Update on Formulation of New Business Strategy

April 12, 2024 9:27 AM

INFORMATION ON ENZOLYTICS, INC.BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICERUPDATE ON FORMULATION OF NEW BUSINESS STRATEGYALLEN, TX / ACCESSWIRE / April 12, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com) (the "Company") today released resume information on its new board of directors and chief financial officer.The new board of directors consists of Harry Zhabilov, Chairman; Dr. Lachezar Ivanov, and Dr. Gaurav Chandra.Harry...

Read more

ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments

April 12, 2024 9:00 AM

VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), an artificial intelligence-driven biotherapeutic research and technology company in what they stated is a landmark collaboration.Featured photo by CDC on Unsplash. Between June 2022...

Read more

Vicore to Present at Upcoming Investor Conferences

April 12, 2024 5:20 AM

STOCKHOLM, SE / ACCESSWIRE / April 12, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, April 12, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:Kempen Life Sciences ConferenceLocation: Amsterdam, HollandDate: April 16Company Participants: Hans Jeppsson, CFO, and Bertil...

Read more

DiviTum(R) TKa in Observational Trial

April 12, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / April 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida. If successful, it will further validate the utility of DiviTum TKa as an effective tool for disease monitoring."The study evaluates DiviTum TKa's capacity as a predictive blood-based biomarker that can...

Read more

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

April 11, 2024 9:00 AM

TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario.Edesa's Chief Executive Officer Par Nijhawan, MD, is scheduled to present on...

Read more

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024 9:00 AM

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billionShareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectivelyAcceptance period has commenced and will end on May 13, 2024, at 24:00 hours CESTPLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 11, 2024 / The Management Board and Supervisory...

Read more

Nomination Committee for Biovica International AB for the 2024 Annual General Meeting

April 11, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / April 11, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The Nomination Committee prior to the 2024 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2023, and the Chairman of the Board. The Nomination Committee then appoints a...

Read more

Ondine Biomedical Inc. Announces Steriwave Authorized for use by HCA UK

April 10, 2024 2:00 AM

Steriwave authorized for use by HCA UKLight-activated antimicrobial that does not generate antimicrobial resistance (AMR) approved for use in healthcare facilities operated by leading private healthcare provider HCA Healthcare UKVANCOUVER, BC / ACCESSWIRE / April 10, 2024 / Leading private healthcare provider, HCA Healthcare UK, has approved the Steriwave® light-activated antimicrobial developed by Ondine Biomedical Inc. (LON:OBI) for use in its...

Read more

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

April 9, 2024 8:45 AM

Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew...

Read more

Data4Cure Announces a Late-Breaking Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

April 8, 2024 5:15 PM

WALTHAM, MA / ACCESSWIRE / April 8, 2024 / Data4Cure, a leading biomedical data-to-knowledge company, today announced a late-breaking research poster presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5 to April 10, 2024, in San Diego, California.Data4Cure researchers will demonstrate how the company's Biomedical Intelligence platform enables deep interrogation and actionable insights...

Read more

CARDIO inCode-Score Clinical Publication on Polygenic Risk of Coronary Heart Disease

April 5, 2024 9:00 AM

US Study Publication in the American Journal of Preventive CardiologyOXFORD, UK / ACCESSWIRE / April 5, 2024 / GENinCode Plc (www.genincode.com) the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces today the publication by the American Journal of Preventive Cardiology of a study on ‘Polygenic Risk and Incident Heart Disease in a large multiethnic cohort'1.. The Kaiser Permanente Division of...

Read more

Indica Labs and Molecular Instruments Announce Partnership to Advance AI-Powered Quantitative Image Analysis with HCR(TM) RNA-ISH

April 5, 2024 8:00 AM

ALBUQUERQUE, NM and LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / Indica Labs, a leading provider of AI-powered digital pathology solutions, and Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology, announce a new partnership to co-market compatibility between MI's patented HCR™ Imaging technology and Indica's HALO® software. HCR™ RNA-ISH sets a new industry standard with its array of clinical-grade features including...

Read more

BioInvent International AB Publishes Annual Report 2023

April 4, 2024 7:55 AM

LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been published. The Annual Report is attached to this press release in pdf format and is available on the company's website,...

Read more

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

April 4, 2024 2:50 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / April 4, 2024 / Vicore Pharma Holding (STO:VICO) The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "Company"), with its registered offices in Stockholm, are summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 in the premises of the law firm Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 13.45.Shareholders can...

Read more

Ondine Biomedical Inc. Announces Entry into ICU Market Expands Revenue Potential

April 4, 2024 2:00 AM

Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) marketTreatment of patients in ICUs would significantly expand Ondine's potential market opportunity.Hundreds of thousands of patients are admitted to the ICU every year in Canada alone, with an average stay of over four days. [1]One in every eight patients in Canadian ICUs develops an infection not related to their presenting medical illness....

Read more

Genflow Biosciences PLC Announces Successful Placing and Subscription

April 4, 2024 2:00 AM

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.MARKET SOUNDINGS WERE TAKEN IN...

Read more

Study Shows hTERT Vaccination Induces Immunological Responses and Prevents Progression in a Subset of Therapy-Resistant Poor Prognosis Cancer Patients

April 3, 2024 9:00 AM

WASHINGTON, DC / ACCESSWIRE / April 3, 2024 / In a significant stride towards active immune therapy of cancer, a recently featured article in Experimental Biology and Medicine (Volume 249, Issue 1) describes a Phase 1 clinical trial, led by James Spicer and colleagues at King's College London. Entitled "A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor...

Read more

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

April 3, 2024 8:00 AM

Clairvoyant on target for potential commercialization of psilocybin treatment in 2025VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD), today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment....

Read more

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

April 3, 2024 7:00 AM

TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents...

Read more

The BWB Awards at Biotech Week Boston Return for a Celebratory Gala September 23rd, 2024

April 2, 2024 11:45 AM

BOSTON, MA / ACCESSWIRE / April 2, 2024 / The BWB Awards at Biotech Week Boston returns for a night of dinner, drinks, entertainment, and the recognition of the top individuals, companies, and organizations in the life sciences community. Since 2018, the Awards at the Biotech Week Boston festival have been bringing together the faces and names that make the Boston community the beating heart of the biotech world. Join 200+ leaders across the...

Read more